Samsung Pharm (001360.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7001360007

Price
1,203.00 KRW
Market cap
113.23 bn KRW
P/E (2025)
9.81
P/S (2025)
2.46
Dividend yield
0.00 %
Net margin
25.06 %
Return on equity (ROE)
9.54 %
Return on assets (ROA)
6.90 %

Samsung Pharm financials

Fiscal year20242025
Revenue44.29 bn KRW46.07 bn KRW
Gross profit19.77 bn KRW13.98 bn KRW
Operating income-14.83 bn KRW-18.07 bn KRW
EBIT-13.86 bn KRW12.74 bn KRW
Net income-14.09 bn KRW11.55 bn KRW
Diluted EPS – continuing operations-149.72 KRW122.66 KRW

Full history since 2012, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Samsung Pharm

SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamins, antibiotics, and others. The company also provides medicines for the digestive system, medicines for liver disorders, medicines for the circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, cold medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.